Fig. 3.
Different decay kinetics of anti-Spike and anti-RBD IgG versus IgA in saliva from participants receiving COVID-19 mRNA vaccines. Saliva from n = 32 LTCH participants was assessed for the presence of IgG (A, B), IgA (C, D), and SIgA (E, F) antibodies against Spike (A, C, E) or RBD (B, D, F). The Wilcoxon signed-rank test was used to calculate significance between groups. ns not significant, *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.